Macugen To Get Advisory Committee Review For Macular Degeneration; NDA Will Be Complete Q3

Pfizer/Eyetech's Macugen (pegaptanib) NDA for treatment of "wet" age-related macular degeneration will be considered at the Aug. 27 meeting of FDA's Dermatologic & Ophthalmic Drugs Advisory Committee. Pivotal trials show efficacy in all three AMD subtypes, but also show inverse dose response.